Table 1.
The clinical characteristics of the training and validation cohorts.
| Characteristics | Training cohort | Validation cohort | Validation cohort |
|---|---|---|---|
| GSE10846 | GSE31312 | GSE87371 | |
| n=400 | n=466 | n=216 | |
| Gender | |||
| Female | 167(41.75%) | 196(42.06%) | 101(46.76%) |
| Male | 216(54.00%) | 270(57.94%) | 115(53.24%) |
| Unknown | 17(4.25%) | – | – |
| Age | |||
| ≤60 years | 185(46.25%) | 200(42.92%) | 113(52.31%) |
| >60 years | 215(53.75%) | 266(57.08%) | 103(47.69%) |
| Stage | |||
| I- II | 186(46.50%) | – | 71(32.87%) |
| III-IV | 208(52.00%) | – | 145(67.13%) |
| Unknown | 6(1.50%) | – | – |
| COO | |||
| GCB | 181(45.25%) | – | 82(37.96%) |
| Non-GCB | 219(54.75%) | – | 134(62.04%) |
| ECOG PS | |||
| 0-1 | 291(72.75%) | 372(79.83%) | – |
| 2-4 | 86(21.50%) | 94(20.17%) | – |
| Unknown | 23(5.75%) | – | – |
| LDH | |||
| Normal | 167(41.75%) | 148(31.76%) | – |
| >ULN | 175(43.75%) | 275(59.01%) | – |
| Unknown | 58(14.50%) | 43(9.23%) | – |
| ES | |||
| <2 | 342(85.50%) | 364(78.11%) | – |
| ≥2 | 29(7.25%) | 102(21.89%) | – |
| Unknown | 29(7.25%) | – | – |
| Survival status | |||
| OS years (median) | 2.45 | 2.95 | 3.06 |
| Censored(%) | 151(37.75) | 167(35.84) | 45(20.83) |
COO, cell of origin; GCB, germinal center B-cell-like subtype; ECOG PS, The Eastern Cooperative Oncology Group performance score; LDH, lactate dehydrogenase; ULN, the upper limit of normal; ES, extranodal sites; OS, overall survival.